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TheinvitroandinvivoevidencecompatiblewitharoleforoxidativestressinOTAcarcinogenicityhasbeen collectedanddescribed.
Several potential oxido-reduction mechanisms have been identiﬁed in the past. More recently, the possibility of a reduction of
cellular antioxidant defense has been raised as an indirect source of oxidative stress. Consequences resulting from the production
of oxidative stress are observed at diﬀerent levels. First, OTA exposure has been associated with increased levels of oxidative DNA,
lipid, and protein damage. Second, various biological processes known to be mobilized under oxidative stress were shown to
be altered by OTA. These eﬀects have been observed in both in vitro and in vivo test systems. In vivo, active doses were often
within doses documented to induce renal tumors in rats. In conclusion, the evidence for the induction of an oxidative stress
response resulting from OTA exposure can be considered strong. Because the contribution of the oxidative stress response in the
development of cancers is well established, a role in OTA carcinogenicity is plausible. Altogether, the data reviewed above support
the application of a threshold-based approach to establish safe level of dietary human exposure to OTA.
1.Introduction
Ochratoxin A (OTA) is a mycotoxin produced by several
food-borne species of Aspergillus and Penicillium fungi. OTA
occurs in various food materials and therefore humans
are continuously exposed to relatively small amounts of it.
Because of its wide occurrence and consequent exposure,
together with a potent carcinogenic potential in animal
models, OTA has attracted signiﬁcant publichealth attention
over the last few years. Several national and international
food safety organizations and expert groups have conducted
a thorough review of the situation as well as risk assessments
in order to provide an insight on the health signiﬁcance of
OTA in food.
Human epidemiology has been inconclusive: a number
of studies have suggested a correlation between exposure to
OTAandBalkanEndemicNephropathy(BEN)andmortality
from urinary tract tumors [1, 2]. Epidemiological data
were recently reviewed by several expert groups [3–6].
All concluded that causality between intake of OTA and
human nephropathy could not be established. Therefore,
the IARC statement that there is inadequate evidence for
carcinogenicity in humans (group 2B) [7] appears still valid.
Recently, other nephrotoxic agents have been put forward as
t h ep r i m a r yc a u s eo fB E N[ 6, 8, 9].
In absence of adequate human data, risk assessments
havereliedonanimaldata.Kidneyhasbeenconsideredasthe
keytargetorganofOTAtoxicity.Inallanimalspeciesstudied,
OTA was found to produce renal toxicity, while in rodents
renal carcinogenicity was clearly established. Recently, OTA
renal and hepatic carcinogenicity was also observed in chicks
[10]. Using a LOAEL of 8mcg/kgbw/day based on early
markers of renal toxicity in pig (the most sensitive animal
species) and applying an uncertainty factor of 450, EFSA [4]
allocated a Tolerable Weekly Intake (TWI) of 120ng/kgbw.
AnalysisofdietaryexposurethroughoutEuroperevealedthat
the current average OTA exposure (50–60ng/kgbw/week)
is well within the TWI [4]. The joint FAO/WHO Expert
Committee on Food Additives (JECFA) ﬁrst evaluated OTA
at their 37th meeting [11]. Based on the LOAEL in pig, and2 Journal of Toxicology
applying an uncertainty factor of 500, JECFA allocated a
Provisional Tolerable Weekly Intake (PTWI) of 112ng/kgbw
[11]. This value was rounded to 100ng/kgbw/week and
conﬁrmed in several subsequent meetings [12, 13].
In 2008, JECFA applied a benchmark dose (BMD) mod-
eling approach using carcinogenicity data [14]. The BMD
is the dose estimated to cause a predeﬁned increase (e.g.,
10% for the BMD10) in tumor incidence over background.
The BMDL is the lower limit of a one-sided 95% conﬁdence
interval of the BMD. The occurrence of combined adenomas
andcarcinomas in thekidneysof malerats was consideredby
JECFA to be the most appropriate data for modeling. Values
of 18–33mcg/kgbw/d and 15–25mcg/kgbw/day were calcu-
lated for, respectively, the BMD10 and BMDL10.Because the
BMD approach did not provide a lower point of departure
than the LOAEL in pig, JECFA decided to reconﬁrm the
PTWI of 100ng/kgbw/day [14].
A recent health risk assessment, performed by Health
Canada[15]recommends to regulate OTA as a nonthreshold
carcinogen, because of the uncertainties regarding the mode
of action. The authors deﬁned a negligible cancer risk intake
(NCRI, risk level 1:100 000) using the tumorigenic dose at
which 5% of rats are likely to develop tumors (TD05, derived
through modeling) as point of departure. Importantly, there
isconsiderableconvergencebetweenthe NCRIestablished in
this assessment and the TDI derived by EFSA.
In the risk assessment of carcinogenic substances, con-
sideration of the mode of action (MOA) is essential, deter-
m i n i n gt h em e t h o dt ob ea p p l i e di no r d e rt od e ﬁ n el e v e l s
of exposure below which a low safety concern is expected.
The key events analysis framework of the MOA has not yet
been formally applied to OTA. However, the approach used
by most expert groups (EFSA, JECFA, ILSI) to establish the
safe level of exposure of OTA (based on uncertainty factors)
implies the consideration of key events compatible with a
threshold eﬀect. For these groups, amongst the mechanisms
of action highlighted as possible, oxidative stress has been
presented as one of the most probable [5, 14].
1.1. Scope of the Paper. Over the last decades, studies
aimed at elucidating the modes of action implicated in
OTA toxicity and carcinogenicity have been published [16].
There has been considerable debate for many years over the
genotoxicityofOTA and itsactual role in carcinogenicity [3–
5, 11–15, 17, 18].
Although genotoxicity is likely to play a role in OTA
carcinogenicity [3, 4], the actual molecular mechanism
involved, eitherthrough covalentadduct formation, through
other indirect modiﬁcations, or both is still unclear. The
potential of OTA to form covalent DNA adducts has been
subjected to debate due to conﬂicting data in the literature.
Using 32P-postlabelling analysis, large numbers of putative
OTA-derived DNA adducts have been reported to be present
in a wide range of tissues from OTA-treated rats, mice as well
as pigs [2, 17, 19–22]. However, so far, these adducts have
never been observed by any other highly speciﬁc techniques
such as radioactivity measurements using 3H-labelled OTA
(3H-OTA) [23], accelerator mass spectrometry (AMS) [24],
or liquid chromatography-tandem mass spectrometry (LC-
MS/MS) [25].
The present paper is not intended to provide a thorough
review of the complex and controversial scientiﬁc literature
on DNA-adductformation. However, it is important to keep
in mind that DNA adducts are increasingly considered as
markers ofexposures andnot onlyofeﬀects[26, 27]an dthat
DNA-covalent binding does not necessarily determine the
shape of the dose-response at low level of exposure [28, 29].
According to Mantle and coworkers [21, 30], experimental
dose-response data for OTA’s renal carcinogenesis makes a
compelling case for OTA being a thresholded carcinogen in
malerat.Inthiscontext,itappearsimportanttoalsoconsider
other potential modes of action, which could potentially
contribute to OTA carcinogenicity. In the near future, the
application of the mode of action framework [28]w i l l
likely help to understand the individual contribution of all
mechanisms described up to now for OTA.
The focus of the present short paper was to collect and
highlight the evidence associated with a role for oxidative
stress as a plausible mechanism to consider for OTA. A list of
thestudiesusedtoillustrate themainmessagesofthepresent
paperisprovidedinTable 1.Althoughnotexhaustive, thelist
shows that over the last two decades, numerous investigators
havedocumentedthegenerationofoxidativestressasaresult
of OTA treatment in both in vitro and in vivo model systems.
2.SourcesofOTA-Mediated
Oxygen-SpeciesGeneration
Production of reactive oxygen species (ROS) leading to
oxidative stress and macromolecular damage is known to
contribute to the pathogenesis of age-related as well as
chronic diseases including cancer [31–35]. A number of
studies are available documenting that OTA is associated
with the production of reactive oxygen species and resulting
oxidative stress through various direct and indirect mecha-
nisms.
2.1. Oxido-Reduction Mechanisms. Several oxido-reduction
mechanisms elicited by OTA have been proposed. In a
reconstituted system consisting of phospholipid vesicles, the
ﬂavoprotein NADPH-cytochrome P450 reductase and Fe3+,
OTA was found to chelate ferric ions (Fe3+), facilitating
their reduction to ferrous ions (Fe2+), which in the presence
of oxygen, provided the active species initiating lipid per-
oxidation [36]. Results indicated that the hydroxyl radical
was not involved in the process. A role for cytochrome
P450 in this reaction was also suggested [36]. In contrast,
others found that OTA induced oxidative damage through
the generation of hydroxyl radicals. This reaction conducted
with microsomes, in presence of NADPH and O2 did not
require exogenous Fe [20]. Structure-activity studies have
also suggested that the toxicity of OTA may be attributable
to its isocoumarin moiety and that the lactone carbonyl
group may be involved in its toxicity. Using a Bacillus
brevis model, Hoehler’s et al. showed that OTA behaved as
a cell pro-oxidant through mobilization of Fe2+ and Ca2+Journal of Toxicology 3
Table 1: OTA oxidative stress-related studies.
Model Gender Via Time
treatment Dose Aim Results/Conclusion Ref.
BALB/c
macrophage J774a
cell line
24, 48, 72h 30nM–100μM
OTA
immunotoxicity
and modulation
inﬂammatory
process
Induction of iNOs,
COX-2 and NF-κb
expression by OTA. OTA
is an immunotoxic
compound
[51]
Porcine kidney
tubuli cells LL-PK1 6–24h 1–100μmol/L
Characterization
eﬀect of OTA on
Nrf2 response
Nrf2 potential signal
transduction pathway by
which OTA impairs its
own detoxiﬁcation
[45]
Porcine kidney
tubuli cells LL-PK1 24h 1–100μmol/L
Impact of OTA on
Nrf2, AP-1 activity,
antioxidant
enzymes and GST
Enhanced production of
ROS, GST impairment.
Nrf2 and AP-1
disruption by OTA.
Impairment of the
detoxiﬁcation machinery
[44]
Rat
Sprague-Dawley male diet 15 days 3.0mg/kg bw Oxidative stress
protection study
OTA-induced oxidative
stress chemoprotection
by Inula crithmoides
[102]
Rat F344 male gavage 7 and 21 days 0.5mg/kg bw
Mechanism of
action
study-microarrays
Oxidative stress, calcium
homeostasis,
cytoskeleton structure
[61]
Human
hepatocytes
HepG2; Monkey
kidney Vero cells
0–100μMD e c r e a s e G S H No induction of heat
shock protein (HSP) [103]
Rat Wistar male diet 15 days 5ng/gbw
50ng/kg bw
Oxidative damage
study (proteins and
lipids)
Malondialdehyde
(MDA) and protein
carbonylation (PC)
increase in kidney > liver
[76]
Chinese Hamster
lung V79 cells;
Lymphoma mouse
LY5178 cells
0–438μMO T A m u t a g e n i c i t y
OTA is mutagenic at
cytotoxic doses in
mammaliancells via
oxidative DNA damage
induction.
[104]
Rats
Sprague-Dawley male diet 4 weeks 200ppb Oxidative stress
protection study
OTA-induced oxidative
stress and DNA damage
chemoprotection by
cyanidin
3-O-β-D-glucoside
[105]
Pig kidney cell line
LLC-PK1 24h 0, 10, 15, 20μM Oxidative stress
protection study
OTA-induced ROS.
Scavenging by
cathechins
(epigallocathechin
gallate (EGCG) and
epicatechin gallate
(ECG))
[106]
Human epithelial
colorectal
adenocarcinoma
Caco-2 cells
100μM
Eﬀect of OTA on
barrier function
impairment
Loss of microdomains
associated with tight
junctions maybe due to
oxidative events
[107]
Neural
stem/progenitor
cells (NSCs)
0.01–100μg/mL
Vulnerability of
brains mouse cells
to OTA
Robust increased in total
and mitochondrial SOD
activity. OTA impaired
hippocampus
neurogenesis
[108]4 Journal of Toxicology
Table 1: Continued.
Model Gender Via Time
treatment Dose Aim Results/Conclusion Ref.
Rats Male/liver
and kidney
Diet (drinking
water) 4 weeks 289μg/kg Oxidative stress
protection study
Melatonin protection
against OTA-induced
oxidative damage in liver
and kidney. CoQ
protective in liver.
[79]
Human renal cell
line HK-2 6a n d2 4h 5 0μM
Mechanism of
action
study-microarrays
Signiﬁcantincrease in
ROS level and oxidative
DNA damage.
[61]
Human renal
proximal tubular
epithelial cell line
HK-2
50–800μM
Evaluate
single-strand DNA
breaks and
oxidative damage
induction by OTA
Oxidative stress precedes
cytotoxicity and
genotoxicity
[57]
Male Fischer 344;
Primary
hepatocytes;
adherent proximal
tubules epithelial
NRK cells; rat liver
RL-34
Rats 2 years;
in vitro
culture
24–48h;
300μg–
100/kgbw;
1.5–6.0μM
Demonstration of
cellular defense
reduction by OTA
OTA induces depletion
of antioxidant defense by
inhibition of Nrf2
responsible of oxidative
stress response
[46]
E k e ra n dw i l dt y p e
rats male gavage 1–14 days 210μg/kgbw
Early
carcinogen-speciﬁc
gene expression
study
Oxidative DNA damage
response genes, general
stress response, and cell
proliferation
[109]
Wistar rats gavage 90 days 289μg/kgbw
Early eﬀects of
chronic OTA
administrationin
liver
Reduction in the ability
to counteract oxidative
stress in liver
[63]
Swiss ICR male i. p 6, 24, 72
hours 0–6mg/kgbw
Oxidative stress
and OTA
neurotoxicity
Acute depletion of
striate DA on a
background of globally
increased oxidative stress
and transient inhibition
of oxidative DNA repair
[110]
Swiss mice male I.p; infusion 2 weeks
Acute 3.5mg/kg;
chronic 4, 8,
16mg/kg
Eﬀect of chronic
low dose OTA
exposure on
regional brain
oxidative stress and
stratial DA
metabolism
Low doses exposure
caused global oxidative
stress
[111]
F344 rats male diet
7 and 21d; 4,
7a n d1 2
months
300mg/kgbw
OTA mechanism of
action-microarrays
study in liver and
kidney
Oxidative stress and
metabolic response
modulated involving
mainly Nrf2 and HNF4α
pathway disruption
[47]
Swiss mice male oral 24 hours 10mg/kg
Immune cells
response after
acute OTA
exposure
OTA-induced oxidative
stress response
responsible of its own
toxicity.
[112]
Wistar rats female Intraperitoneally 7, 14 and 21
days 0.5mg/kgbw/day
Genotoxic
potential of OTA
measuring DNA
strand breaks
(comet assay) in
the kidney
OTA-induced DNA
strand breaks were
detected, OTA
concentration in the
kidney and duration of
the treatment correlated
with severity of the DNA
damage
[62]Journal of Toxicology 5
Table 1: Continued.
Model Gender Via Time
treatment Dose Aim Results/Conclusion Ref.
Wistar rats male Oral 15 days 5ng; 0.05mg;
0.5mg/bw
Eﬀect of OTA on
DNA damage
Oxidative stress
responsible for
OTA-DNA damage as
shown by Fpg-modiﬁed
comet assay
[113]
Pig kidney
microsomes,
human bronchial
epithelial cells,
human kidney cells
C e l l s :2 ,7 ,2 4
hours 0.5, 1.0, 2.5μM
Genotoxicity of the
hydroquinone
(OTHQ)
metabolite of OTA
OTQ-mediated adduct
spots form in a dose-
and-time-dependent
manner
[114]
Wistar rats female oral 7, 14 and 21
days 0.5mg/kgbw
Eﬀect of OTA on
protein oxidation
in kidney and liver
Increased protein
carbonyls in the kidney
and liver
[68]
F344 rats male gavage 0.03, 0.10,
0.30mg/kgbw
Evaluate relevance
of OTA-induced
oxidative damage
on nephrotoxicity
and
carcinogenicity
Tumours in rat kidney
may be attributable to
oxidative DNA damage
in combination with
cell-speciﬁc cytotoxic
and
proliferation-stimulating
eﬀects as cell-signaling
response
[69]
V79 (Chinese
hamster lung
ﬁbroblasts) cells,
CV-1 (African
green monkey,
kidney) cells,
primary rat kidney
cells
1–24 hours 2.5, 100μmol/L
OTA
Relevance of
OTA-induced
oxidative damage
in nephrotoxicity
and
carcinogenicity
Cytotoxicity and
oxidative DNA damage
already at low doses
could be a relevant
factor for the
nephrocarcinogenicity
[58]
Rat lymphoid cells 1 hour 0.5, 2, 20μM
OTA immune
function
modiﬁcation
Protein synthesis
inhibition, oxidative
metabolism of OTA,
prostaglandin synthesis
implicated in NK cells
toxicity
[115]
Human
hepatoma—
derived cell lines
(HepG2), human
colonic
adenocarcinoma
cell line (Caco-2)
24, 48, 72
hours 0–100μM Oxidative stress
protection study
OTA-induced oxidative
stress damage. Protective
eﬀect by
Cyanidin-3-O-β
glucopyranoside
(C-3-G)
[116]
F344 Fischer rats male gavage 2 weeks 0–2000μg/kgbw Genotoxicity of
OTA
DNA strand breaks in
target and nontarget
tissues probably
involving oxidative stress
mechanism
[60]
Human
hepatoma—
derived cell line
(HepG2)
48–72 hours 35–10mM Oxidative damage
protection study
No cytotoxicity
protection observed with
Vitamine E, polyphenols
[117]
Sprague-Dawley male diet 15 days 3mg/kg
Oxidative stress
protection in vivo
study
Preventive eﬀect against
OTA-induced oxidative
stress and lipid
peroxidation by
melatonin
[75]6 Journal of Toxicology
Table 1: Continued.
Model Gender Via Time
treatment Dose Aim Results/Conclusion Ref.
Human ﬁbroblast
cells 48–72 hours 0–50μM Oxidative stress
protection study
Reduction of free radical
species production and
DNA damage prevention
by cyanin
3-O-β-D-glucoside
(C3G)
[118]
Fetal rat
telencephalon
aggregating cells
24–48 hours,
9d a y s 0–20nM Adverse eﬀect of
OTA in brain
Brain inﬂammatory
response induction of
HO-1, iNOs, PPARγ,
cytoskeletal damage
[50]
Human
hepatoma-derived
cell line (HepG2)
24 hours 0–40μg/mL Genotoxicity of
OTA
Dose-dependent
induction of DNA single
strand breaks (comet
assay) and micronuclei
(MN)
[119]
Primary proximal
tubules renal (PT)
cells, proximal
tubular cell line
(LLC-PK1)
0–24 hours 0–100μM
OTA mediated
oxidative stress
response in
proximal tubular
cells, oxidative
stress protection
Oxidative stress
contributes to tubular
toxicity. Antioxidants
(α-tocopherol,
N-acetyl-Lcysteine
(NAC) treatment
prevents OTA toxicity
[59]
Wistar rats male gavage 10, 30, 60
days 120μg/kgbw
Kidney low dose
OTA response:
sequence of events
leading to cell
death
Low dose induces
oxidative stress,
apoptosis in proximal,
and distal tubule kidney
cells
[78]
Human
hepatoma—
derived cell line
(HepG2)
1h o u r ,2 4
hours 0–50μg/mL Genotoxicity of
OTA
No inductions of
mutations in the Ames
assay, a dose-dependent
induction of micronuclei
in the MN assay, and
DNA migration (comet
assay)were detected
[120]
Proximal tubular
cells (PTC), Wistar
rats
male gavage
24–72 hours
(in vivo and
in vitro)
5.0μM, 12.5μM
in vitro;1a n d
10mg/kgbw
In vivo and in vitro
gene expression
comparative study
In vitro and in vivo gene
expression data were
comparable. Response to
oxidative stress-related
genes hypoxia-inducible
factor 1 and catalase was
observed
[121]
Dark Agouti (DA),
Lewis rats male Intragastric
intubation 0.4mg/kgbw Life-time
Life-time study to
evaluate if MESNA
leads to a more
eﬀective reduction
of OTA-induced
tumour
development or
urinary tract
damage
Lack of eﬀect of mesna
on OTA-induced urinary
tract damage or renal
tumor development
[122]
Dark Agouti (DA),
Lewis rats male Intragastric
intubation 0.4mg/kgbw 2 years
Life-time study to
evaluate the
potential protective
eﬀect of 2
mercaptoethane
sulfonate
(MESNA) and
N-acetyl cysteine
(NAC )
MESNA decreased
karyomegalies in kidney,
but had no beneﬁcial
eﬀect on renal tumour
incidence
[123]Journal of Toxicology 7
Table 1: Continued.
Model Gender Via Time
treatment Dose Aim Results/Conclusion Ref.
Fischer rats male gavage 4, 8, 24, 48
hours 0–2.0mg/kgbw
Chemical and
biological markers
induced by OTA
exposure
associated with
oxidative stress
Oxidative stress may
contribute to
mechanism of OTA renal
toxicity and
carcinogenicity in rats
over long term exposure
[77]
Bronchial
epithelial cells
incubated with
microsomes of
seminal vesicles of
pig
4h o u r s 1 0μM
Roles of
cyclooxygenase
and lipoxygenase
in ochratoxin A
genotoxicity in
human epithelial
lung cells
OTA is biotransformed
into genotoxic
metabolite via a
lipoxygenase, whereas
prostaglandin—H-
synthetase (PGHS)
decreases OTA
genotoxicity
[124]
Sprague-Dawley
liver microsomes,
liver mitochondria
and hepatocytes
cells
female 2.5mM
Free radical
generation by OTA
in hepatocytes,
mitochondria, and
microsomes using
electron
paramagnetic
resonance (EPR)
Oxidative damage may
be one of the
manifestations of
cellular damage in the
toxicity of OTA
[125]
Bacillus brevis 10min 1mg/mL
Study free radical
generation in
bacteria as model
system
OTA induces free radical
production, enhancing
permeability of the
cellular membrane to
Ca2+
[37]
Swiss mice Male Gastric
intubation 48 hours 2mg/kgbw
Eﬀects of vitamins
on genotoxicity of
OTA
Vitamins E, A, and C
also reduced OTA-DNA
adduct formation in
mice kidney
[126]
Wistar rat male Gastric
intubation
Every 48
hours/3
weeks
289μg/kg body
weight
Protective eﬀect of
superoxide
dismutase (SOD)
and catalase
SOD + catalase prevents
the nephrotoxicity
induced by OTA in rats
[127]
Wistar rat liver
microsomes,
kidney microsomes
male 6mg/kgbw Lipid peroxidation
induction by OTA
lipid peroxidation may
play a role in the
observed toxicity of
ochratoxin A
[73]
pathway leading to uncoupling oxidative phosphorylation
and increased production of hydroxyl radical via the Fenton
reaction [37]. However, in other studies using OTA and
structural analogs, a direct correlation between toxicity and
iron chelating capacity was only partially supported [38].
ThegenerationofanOTAhydroquinone/quinonecouple
from the oxidation of OTA (phenol oxidation) by elec-
trochemical, photochemical, and chemical processes was
reported [39, 40]. The quinone is thought to undergo reduc-
tions to form hydroquinone, postulated to be responsible
for the formation of the glutathione conjugate of OTA.
Such events are likely to result in redox cycling and in
the generation of reactive oxygen species [20, 40, 41]. The
formation of OTA-derived quinones has been observed in
cell cultures in vitro [41]a sw e l la sin vivo [42, 43].
2.2. Reduction of Antioxidant Defenses. OTA was found to
reduce the expression of several genes regulated by nuclear
factor-erythroid 2 p45-relatetd factor (Nrf2) [44–47]. This
was observed at the RNA and protein levels, both in vitro
and in vivo test systems. Nrf2 is involved in both the basal
expression as well as in the induction of genes encoding
detoxiﬁcation, cytoprotective, and antioxidant enzymes [48,
49]. A reduction of the expression of these genes is likely to
result in decrease in antioxidant defenses leading tooxidative
stress andmacromolecular damage.This was conﬁrmedwith
OTA. Through in vitro and in vivo studies, a correlation
was observed between the OTA-dependent reduction of the
Nrf2 pathway and an increased production of oxidative
damage [46]. In this context, it is interesting to note that
OTA was found to increase the expression of inducible8 Journal of Toxicology
nitric oxide synthase (iNOs) [50–52], an enzyme responsible
for the production of nitric oxide (NO). An association
between iNOs expression and the development of cancers
was suggested in humans and animals in vivo [53]. In excess,
NO may behave as a toxic radical producing nitrosative
stress. NO is known to react with oxygen anion radical
superoxide to form the pro-oxidant peroxynitrite. Under
physiological conditions, peroxynitrite rapidly decomposes
to generate a nitro radical intermediate leading to protein
and DNA nitration. OTA was shown to stimulate protein
and possibly DNA nitration [52, 53] indicating that OTA
exposure may be considered as a source of both oxygen and
also reactive nitrogen radicals/species (RNS).
3.OTA-MediatedOxidativeDamage
3.1.DNA-Damage. ROS,such ashydroxyl radicals and nitric
oxide, are capable of forming oxidized DNA bases that
directly produce diverse types of DNA damage [54–56].
The oxidized DNA bases appear to be capable of inducing
mutations that are commonly observed in neoplasia [33]. As
illustrated in Table 1, diverse biomarkers have been analyzed
showing that OTA induces DNA damage. In cell cultures,
the OTA-dependent production of ROS was correlated with
an increased formation of 8-oxoguanine [57–59]. Moreover,
OTA was shown to induce DNA strand breaks as assessed
by comet assay in liver, kidney, and spleen of F344 rats
given 0, 0.25, 0.50, 1.0, and 2.0mg/kgbw/day by gavage
for 2 weeks [60]. In liver and kidney, the extent of DNA
damage analyzed by comet assay was further enhanced in
the presence of formamidopyrimidine glycosylase (Fpg), an
enzyme involved in excision repair of oxidized DNA bases
[57, 58, 61]. Anotherstudy [62] detected DNA-strandbreaks
(using the comet assay) in the kidney of female Wistar rats
treated intraperitoneally with OTA (0.5mg/kgbw/day for 7,
14, and 21 days; n = 5 per group). The severity of the
DNA lesions in the kidney increased according to the OTA
dose and was at maximum after 21 days of treatment. Other
authors have observed oxidative DNA-damage in various
tissues of animals treated with a wide range of OTA doses
and treatment durations [46, 60, 63, 64].
3.2. Protein Damage. Carbonylation of proteins occurs
through a variety of oxidative pathways [54, 65–67]. Car-
bonylation is an important protein modiﬁcation associated
with alterations of protein (enzymes) function, protein
misfolding, protein fate, and proteolysis. An increase in
protein carbonyl content of tissues has been associated with
a number of pathological disorders. Due to their abundance
in mammalian cells, cytoskeletal proteins like actin are
common targets for a variety of ROS and low-molecular
weight reactive carbonyl species [67]. Inconsistent data have
been reported on the potential impact of OTA on protein
carbonylation [52, 59, 63, 68, 69]. No increase in protein
oxidation was observed in liver and kidney of F344 rats
treated with OTA at 0.3mg/kgbw per day for 4 weeks [69].
The same ﬁnding was reported in liver of Wistar rats treated
with OTA at 289μg/kgbw for 90 days [63]. In contrast, in
another in vivo study measuring protein oxidation in Wistar
rats treated with OTA (0.5mg/kgbw/day) for 24h, 7, 14
and 21 days, a signiﬁcant increase in protein carbonyls was
found after 14 and 21 days of treatment in, respectively, the
kidneyandtheliver[68].Oxidativeproteinmodiﬁcation was
observed in vitro [52].
3.3. Lipid Damage. Lipid peroxidation is among the most
extensively investigated processes induced by free radicals.
Of these, the by-products, 4-hydroxy-2-nonenal (HNE), the
tautomermalondialdehyde(MDA),acroleinandcrotonalde-
hyde have been widely studied. The ability of these reactive
electrophiles to modify DNA bases, yielding promutagenic
lesions, is considered to contribute to the mutagenic and
carcinogenic eﬀects associated with oxidative stress-induced
lipid peroxidation. HNE and MDA have increasingly been
implicated in carcinogenesis [33, 70–72]. OTA has been
reported to increase MDA formation. Initially, Rahimtula’s
group [73] observed that OTA was able to stimulate lipid
peroxidation when added to liver or kidney microsomes
or when administered to rats in vivo. Stimulation of lipid
peroxidation by OTA-iron complex facilitating the reduction
of iron was further reported [36]. Moreover, additional
studies [74] indicated that OTA induced lipid peroxidation
accompanied by leakage of calcium from calcium-loaded
microsomes. Increased formation of MDA was observed
in animal models treated orally with diﬀerent doses of
OTA [75–79]. HNE-protein adducts were measured in cell
cultures treated with OTA [52].
4.OTA-Mediated Biological Response
It is widely acknowledged that reactive oxygen and ni-
trosative species can trigger biological responses such as
stimulation or inhibition of signal transduction and gene
expression. Such biological responses are considered to
contribute to the expression of the carcinogenic potential
of the reactive chemicals. A number of in vitro and in vivo
studies are consistent with a role of oxidative and probably
nitrosative stress as messengers involved in the adverse
biological eﬀects of OTA (Table 1).
5.Cell Signaling
ROS induces release of calcium from intracellular stores,
resulting in the activation of kinases, such as protein kinase
C (PKC). ROS species play also a critical role in the selective
mobilization of other cell signaling responses. Cell signal-
ing phosphoproteins of mitogen-activated protein (MAP)
kinases including ERK, c-Jun N-terminal kinases (JNK), and
p38 kinases are involved in proliferation, diﬀerentiation, and
apoptosis. Activation of these molecules has been observed
in response to changes in the cellular redox balance and
are considered as vectors of ROS biological eﬀects [33]. In
vitro experiments provided evidence of an eﬀect of OTA
on intracellular calcium (Ca2+)h o m e o s t a s i s[ 74, 80–82].
Ca2+ homeostasis modulation by OTA was also observed
in vivo [83]. An increased rate of microsomal Ca2+ uptakeJournal of Toxicology 9
was observed after OTA administration in vivo and in vitro
[84]. Gene proﬁling analysis suggested a modulation of
genes involved in calcium homeostasis by OTA [47, 85].
These data indicate that Ca2+ dependent signal transduction
pathways may be aﬀected by OTA treatment. Interferences
were observed with other cell signaling pathways. OTA was
shown to stimulate phosphorylation of ERK1/2, SAP/JNK,
and p38 using in vitro models [82, 86, 87]. Using an in
vivo model ERK1/2 a speciﬁc signaling response was also
observed with mobilization of the atypical protein kinase C
(PKCζ) and the insulin-like growth factor-1 (IGF-1) system
[88]. Gene proﬁling data supported a potential role of the
(IGF)-PI3K-PKB pathway in OTA-mediated renal toxicity in
male rats [89].
5.1. Redox Modulation of Transcription Factors. Numerous
reports have characterized interactions of ROS and RNS
with activity of transcription factors [90–92]. Transcription
factors contain a conserved redox sensitive cysteine residue;
the oxidation of this residue inactivates the DNA-binding
domain of the factor. Several studies have observed an
inactivation of transcription factors resulting from increased
concentrations of ROS [93–95]. For example, it was shown
that the complex AP-1 is a basic leucine zipper protein,
which is highly sensitive to changes in redox environment
due to a cysteine residue in the DNA-binding domain
[96]. Gene expression proﬁle studies performed using in
vivo models have shown that OTA impairs the antioxi-
dant defense system regulated by Nrf2 [47]. This eﬀect
was supported by further studies [44–46]. Using in vitro
models together with electrophoretic mobility shift assay,
an inhibition of Nrf2 and AP-1 activity was shown as a
result of OTA treatment [46]. Interestingly, Nrf2 binding site
represents a bZip domain that interacts with the Antioxidant
Response Element (ARE) DNA-binding site triggering the
transcription of Nrf2 regulated genes. The ARE motif (5 -
A/GTGAC/TnnnGCA/G-3 ) shares structural similarity with
AP-1 binding site (5 -TGACTCA) involving both cysteine
richresidues,thetargetofROSoxidation[97,98].These data
strongly suggest a correlation betweenthe generationofROS
byOTAandthesubsequentinactivationofNrf2aspreviously
described for AP-1. This molecular mechanism appears as a
likely molecular component explaining the reduction of the
defense response observed under OTA treatment.
In vivo experiments provided direct evidence that S-
nitrosylation can interfere with transcription [91, 92]. Nitric
oxide (NO) induces the nitrosylation of cysteine residues
(thiol groups) within or near the DNA-binding domain
and/or insertion of the zinc ﬁnger, which is a DNA-binding
motif,resultingintheinhibitionoftheDNA-bindingactivity
of transcription factors [99–101]. This is illustrated by the
example of the suppression of P450 gene expression by
NO. NO-donors were found to suppress CYP2D6 promoter
activity through inhibition of the transcription factor called
hepatocyte nuclear factor 4 (HNF4) [94, 95]. Interestingly,
in a gene expression study performed by our group, OTA
was associated with a signiﬁcant reduction of the expression
of genes regulated by HNF4 suggesting an indirect evidence
of the role oxidative stress and the transcription factors
regulation by OTA [47].
5.2. Alterations of Gap-Junction Intercellular Communication
(GJIC). A strong correlation between the ability of a com-
pound to block cell-to-cell communication in cultured cells
and its ability to induce rodent tumors through nongeno-
toxic mechanisms has been documented [33, 128–131].
Disruption of gap junction intercellular communication was
speciﬁcally reported in human renal cancer cell lines [132].
For example, Connexin 32 (Cx32) was discovered to be
generally downregulated in human renal cell carcinoma
(RCC) cell lines and in cancerous regions of the kidney
[133]. ROS such as H2O2, an established tumor promoter,
is known to modulate cell-to-cell communication. Likewise,
certain chemicals inducing ROS were shown to inhibit
intercellular communication in a variety of cells in culture
systems [33]. Data on the potential eﬀects of OTA on GJIC
are inconsistent. Kidney epithelial cells treated with OTA
resulted in modulation of gap junction-mediated intercel-
lular communication, through a reduced expression of the
gap-junction protein CX43 [134]. In addition, OTA strongly
reducedtheexpression ofothergap-junctionproteins,CX26,
CX32, and CX43, in liver of rats treated with OTA [63]. In
another study, even though a strong reduction of CX43 was
found in renal cells in vitro,O T Ai n h i b i t e dG J I Co n l yi nl i v e r
but not in kidney [135].
6.PreventionofOTA-InducedOxidativeStress
6.1. Counteracting OTA-Mediated Reduction of Nrf2 Activity.
As mentioned earlier, OTA was found to reduce the expres-
sion of antioxidant enzymes through inhibition of Nrf2
activity [46]. This reduction in antioxidant gene expression
was correlated with increased oxidative damage of protein
and DNA [46]. To further conﬁrm the actual role of the
reduction of defense mechanisms in the induction of cellular
oxidative damage, inducers of Nrf2 were applied in cell
culturesin vitro.A l lr e p o r t e dO T Ae ﬀectsat thelevelsofNrf2
activity, Nrf2-regulated gene expression, and DNA damage
were prevented in cell pretreated with Nrf2 inducers [46],
strongly indicating a causal relationship between Nrf2 eﬀects
and oxidative damage.
6.2. Application of Radical Scavengers. Several studies have
been performed to try to counteract the adverse eﬀects of
oxygen radicals generated under OTA-treatment. A number
ofmolecules with various antioxidant propertieswere tested,
including inula crithmoides, cyanidin 3-O-b-D-glucoside,
catechins, melatonin, superoxide dismutase, catalase, and N-
acetyl-L-cysteine (NAC), using in vivo or in vitro models.
Protection against OTA-induced DNA damage, lipid peroxi-
dation as well as cytotoxicity was observed [75, 79, 102, 105,
106, 116, 118, 127] further conﬁrming the link between OTA
exposure and oxidative macromolecular damage. However,
up to now, the application of chemicals known to possess
antioxidant properties failed to prevent the development of
OTA-induced tumors in animal models. Authors reported10 Journal of Toxicology
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Figure 1: Scheme to illustrate the oxidative stress-mediated mode of action proposed for OTA. Increased production of ROS, RNS,
and RCS is likely to originate either from direct redox reactions involving OTA or through the inhibition of cellular defenses such as
through the inhibition of transcription factors as Nrf2 which regulates enzymes with antioxidant properties. The generation of radicals
will induce macromolecular oxidative damage such as oxidized DNA bases which may be converted into mutationresulting into generation
of transformed cells. In addition, radicals will trigger biological responses which may impair intercellular communication and induce cell
proliferationas well as reduction in cellular defense in oxidative stress.This lasteﬀect is likelyto amplifythe oxidative stress-mediated eﬀects
of OTA. Altogether, these molecular mechanisms will result in cancer development.
protection against nephrotoxicity but not carcinogenicity
induced by ochratoxin A, implicating two separate pathways
[122, 123].
6.3. Application of Peroxidase Inhibitors. Indomethacin and
aspirin were found to prevent OTA genotoxicity in the
urinary bladder and kidney of mice [136]. These data
suggested the possible co-oxidation of OTA by enzymes
involved in arachidonic acid biotransformation, espe-
cially prostaglandin-H-synthase (PGHS) and/or lipoxyge-
nase [124].Suchreactions thoughttoproduceactivated OTA
metabolites are also known to generate ROS which then may
induce oxidation [124].
7.Conclusion
The carcinogenic mycotoxin OTA has been reviewed by
a number of expert groups [3–5, 14, 137]. These expert
groups identiﬁed the production of oxidative stress as an
important event in the mode of action of OTA-induced
nephrocarcinogenicity. In the present paper, the actual
evidence available supporting such hypothesis was collected
and reviewed.
It has been clearly shown that OTA generates oxida-
tive stress predominantly in kidney through potentially
direct (redox cycling) and indirect (reduction of cellular
antioxidant defenses) mechanisms. Interestingly, these two
mechanisms may interact with each other. The reduction
of defense may amplify the impact of the direct production
of radicals. Consequences resulting from the production of
oxidativestress were observedatdiﬀerentlevels. Highkidney
susceptibility to oxidative stress conditions may explain the
target-speciﬁc toxicity of OTA. Oxidative stress has been
incriminated in a number of kidney pathological pathways
[138–140].
As depicted in Figure 1, ﬁrst, OTA exposure was asso-
ciated with increased levels of oxidative DNA, lipid, and
protein damage. Second, various biological pathways known
to be mobilized under oxidative stress were shown to be
altered by OTA. Importantly, these eﬀects were observed in
both in vitro and in vivo test systems. Active in vivo doses
were within doses known to induce tumors in kidney. These
mechanisms are likely to be relevant for humans.
In conclusion, the evidence for the induction of an
oxidative stress response resulting from OTA exposure can
be considered strong. Because the contribution of the
oxidative stress response in the development of cancers isJournal of Toxicology 11
well established, a role in OTA carcinogenicity is plausible.
Altogether, the data reviewed above support the application
of a threshold-based approach to establish safe level of
dietary human exposure to OTA.
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